HomeCompareACHL vs DIVO

ACHL vs DIVO: Dividend Comparison 2026

ACHL yields 135.14% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACHL wins by $14.87M in total portfolio value
10 years
ACHL
ACHL
● Live price
135.14%
Share price
$1.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.90M
Annual income
$6,066,079.91
Full ACHL calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — ACHL vs DIVO

📍 ACHL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACHLDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACHL + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACHL pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACHL
Annual income on $10K today (after 15% tax)
$11,486.49/yr
After 10yr DRIP, annual income (after tax)
$5,156,167.92/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, ACHL beats the other by $5,155,333.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACHL + DIVO for your $10,000?

ACHL: 50%DIVO: 50%
100% DIVO50/50100% ACHL
Portfolio after 10yr
$7.46M
Annual income
$3,033,530.80/yr
Blended yield
40.64%
📊

Analyst Conviction Gap

Where Wall Street is split right now

ACHL
Analyst Ratings
2
Buy
1
Hold
2
Sell
Consensus: Buy
Price Target
$2.00
+35.1% upside vs current
Range: $2.00 — $2.00
Altman Z
-2.7
Piotroski
1/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACHL buys
0
DIVO buys
0
No recent congressional trades found for ACHL or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACHLDIVO
Forward yield135.14%6.49%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$14.90M$30.7K
Annual income after 10y$6,066,079.91$981.68
Total dividends collected$13.68M$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ACHL vs DIVO ($10,000, DRIP)

YearACHL PortfolioACHL Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$24,214$13,513.51$11,349$649.42+$12.9KACHL
2$56,489$30,580.34$12,833$688.83+$43.7KACHL
3$127,118$66,675.01$14,459$727.90+$112.7KACHL
4$276,241$140,224.56$16,238$766.49+$260.0KACHL
5$580,365$284,787.59$18,179$804.47+$562.2KACHL
6$1,180,170$559,178.96$20,293$841.71+$1.16MACHL
7$2,325,480$1,062,698.63$22,591$878.14+$2.30MACHL
8$4,445,281$1,957,016.59$25,087$913.65+$4.42MACHL
9$8,252,658$3,496,207.78$27,791$948.18+$8.22MACHL
10$14,896,424$6,066,079.91$30,718$981.68+$14.87MACHL

ACHL vs DIVO: Complete Analysis 2026

ACHLStock

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Full ACHL Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this ACHL vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACHL vs SCHDACHL vs JEPIACHL vs OACHL vs KOACHL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.